A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar Rm) in Patients With Advanced Gastric Cancer.
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2014
At a glance
- Drugs Sorafenib (Primary) ; Capecitabine; Cisplatin
- Indications Gastric cancer; Oesophageal cancer
- Focus Biomarker; Therapeutic Use
- Acronyms STARGATE
- 12 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Mar 2014 Planned end date changed from 1 Aug 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 19 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.